Works by Lorigan, Paul

Results: 57
    1

    PARP14 inhibition restores PD-1 immune checkpoint inhibitor response following IFNγ-driven acquired resistance in preclinical cancer models.

    Published in:
    Nature Communications, 2023, v. 14, n. 1, p. 1, doi. 10.1038/s41467-023-41737-1
    By:
    • Wong, Chun Wai;
    • Evangelou, Christos;
    • Sefton, Kieran N.;
    • Leshem, Rotem;
    • Zhang, Wei;
    • Gopalan, Vishaka;
    • Chattrakarn, Sorayut;
    • Fernandez Carro, Macarena Lucia;
    • Uzuner, Erez;
    • Mole, Holly;
    • Wilcock, Daniel J.;
    • Smith, Michael P.;
    • Sergiou, Kleita;
    • Telfer, Brian A.;
    • Isaac, Dervla T.;
    • Liu, Chang;
    • Perl, Nicholas R.;
    • Marie, Kerrie;
    • Lorigan, Paul;
    • Williams, Kaye J.
    Publication type:
    Article
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11

    Modern Management of Small-Cell Lung Cancer.

    Published in:
    Drugs, 2007, v. 67, n. 15, p. 2135, doi. 10.2165/00003495-200767150-00003
    By:
    • Ferraldeschi, Roberta;
    • Baka, Sofia;
    • Jyoti, Babita;
    • Faivre-Finn, Corinne;
    • Thatcher, Nick;
    • Lorigan, Paul
    Publication type:
    Article
    12
    13
    14

    Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''.

    Published in:
    2017
    By:
    • Bowyer, Samantha;
    • Prithviraj, Prashanth;
    • Lorigan, Paul;
    • Larkin, James;
    • McArthur, Grant;
    • Atkinson, Victoria;
    • Millward, Michael;
    • Khou, Muoi;
    • Diem, Stefan;
    • Ramanujam, Sangeetha;
    • Kong, Ben;
    • Liniker, Elizabeth;
    • Guminski, Alexander;
    • Parente, Phillip;
    • Andrews, Miles C;
    • Parakh, Sagun;
    • Cebon, Jonathan;
    • Long, Georgina V;
    • Carlino, Matteo S;
    • Klein, Oliver
    Publication type:
    Letter
    15
    16
    17
    18

    Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma.

    Published in:
    Cancer Immunology, Immunotherapy, 2014, v. 63, n. 5, p. 449, doi. 10.1007/s00262-014-1528-9
    By:
    • Kelderman, Sander;
    • Heemskerk, Bianca;
    • Tinteren, Harm;
    • Brom, Rob;
    • Hospers, Geke;
    • Eertwegh, Alfonsus;
    • Kapiteijn, Ellen;
    • Groot, Jan;
    • Soetekouw, Patricia;
    • Jansen, Rob;
    • Fiets, Edward;
    • Furness, Andrew;
    • Renn, Alexandra;
    • Krzystanek, Marcin;
    • Szallasi, Zoltan;
    • Lorigan, Paul;
    • Gore, Martin;
    • Schumacher, Ton;
    • Haanen, John;
    • Larkin, James
    Publication type:
    Article
    19
    20

    Nivolumab in treating advanced melanoma.

    Published in:
    British Journal of Healthcare Management, 2016, v. 22, n. 6, p. 294, doi. 10.12968/bjhc.2016.22.6.294
    By:
    • Gomes, Fabio;
    • Lorigan, Paul
    Publication type:
    Article
    21
    22
    23
    24
    25
    26

    The role of diabetes in metastatic melanoma patients treated with nivolumab plus relatlimab.

    Published in:
    Journal of Translational Medicine, 2023, v. 21, n. 1, p. 1, doi. 10.1186/s12967-023-04607-4
    By:
    • Mallardo, Domenico;
    • Woodford, Rachel;
    • Menzies, Alexander M.;
    • Zimmer, Lisa;
    • williamson, Andrew;
    • Ramelyte, Egle;
    • Dimitriou, Florentia;
    • Wicky, Alexandre;
    • Wallace, Roslyn;
    • Mallardo, Mario;
    • Cortellini, Alessio;
    • Budillon, Alfredo;
    • Atkinson, Victoria;
    • Sandhu, Shahneen;
    • Olivier, Michielin;
    • Dummer, Reinhard;
    • Lorigan, Paul;
    • Schadendorf, Dirk;
    • Long, Georgina V.;
    • Simeone, Ester
    Publication type:
    Article
    27
    28
    29
    30

    Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East.

    Published in:
    International Journal of Cancer, 2021, v. 149, n. 11, p. 1926, doi. 10.1002/ijc.33746
    By:
    • Ascierto, Paolo Antonio;
    • Orlova, Kristina;
    • Grignani, Giovanni;
    • Dudzisz‐Śledź, Monika;
    • Fenig, Eyal;
    • Chiarion Sileni, Vanna;
    • Fazio, Nicola;
    • Samimi, Mahtab;
    • Mortier, Laurent;
    • Gebhardt, Christoffer;
    • Kramkimel, Nora;
    • Steven, Neil;
    • Bechter, Oliver;
    • Arance, Ana;
    • Benincasa, Elena;
    • Kostkova, Lenka;
    • Costa, Nuno;
    • Lorigan, Paul
    Publication type:
    Article
    31
    32
    33

    A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma.

    Published in:
    Cancer (0008543X), 2014, v. 120, n. 13, p. 2016, doi. 10.1002/cncr.28635
    By:
    • Hamid, Omid;
    • Ilaria, Robert;
    • Garbe, Claus;
    • Wolter, Pascal;
    • Maio, Michele;
    • Hutson, Thomas E.;
    • Arance, Ana;
    • Lorigan, Paul;
    • Lee, Jeeyun;
    • Hauschild, Axel;
    • Mohr, Peter;
    • Hahka‐Kemppinen, Marjo;
    • Kaiser, Christopher;
    • Turner, P. Kellie;
    • Conti, Ilaria;
    • Grob, Jean‐Jacques
    Publication type:
    Article
    34

    Phase 1 study of the pan-RAF inhibitor tovorafenib in patients with advanced solid tumors followed by dose expansion in patients with metastatic melanoma.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 1, p. 15, doi. 10.1007/s00280-023-04544-5
    By:
    • Rasco, Drew W.;
    • Medina, Theresa;
    • Corrie, Pippa;
    • Pavlick, Anna C.;
    • Middleton, Mark R.;
    • Lorigan, Paul;
    • Hebert, Chris;
    • Plummer, Ruth;
    • Larkin, James;
    • Agarwala, Sanjiv S.;
    • Daud, Adil I.;
    • Qiu, Jiaheng;
    • Bozon, Viviana;
    • Kneissl, Michelle;
    • Barry, Elly;
    • Olszanski, Anthony J.
    Publication type:
    Article
    35

    A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation.

    Published in:
    Cancer Chemotherapy & Pharmacology, 2013, v. 71, n. 5, p. 1191, doi. 10.1007/s00280-013-2113-1
    By:
    • Plummer, Ruth;
    • Lorigan, Paul;
    • Steven, Neil;
    • Scott, Lucy;
    • Middleton, Mark;
    • Wilson, Richard;
    • Mulligan, Evan;
    • Curtin, Nicola;
    • Wang, Diane;
    • Dewji, Raz;
    • Abbattista, Antonello;
    • Gallo, Jorge;
    • Calvert, Hilary
    Publication type:
    Article
    36

    Health Economic Consequences Associated With COVID-19–Related Delay in Melanoma Diagnosis in Europe.

    Published in:
    JAMA Network Open, 2024, v. 7, n. 2, p. e2356479, doi. 10.1001/jamanetworkopen.2023.56479
    By:
    • Maul, Lara V.;
    • Jamiolkowski, Dagmar;
    • Lapides, Rebecca A.;
    • Mueller, Alina M.;
    • Hauschild, Axel;
    • Garbe, Claus;
    • Lorigan, Paul;
    • Gershenwald, Jeffrey E.;
    • Ascierto, Paolo Antonio;
    • Long, Georgina V.;
    • Wang-Evers, Michael;
    • Scolyer, Richard A.;
    • Saravi, Babak;
    • Augustin, Matthias;
    • Navarini, Alexander A.;
    • Legge, Stefan;
    • Németh, István B.;
    • Jánosi, Ágnes J.;
    • Mocellin, Simone;
    • Feller, Anita
    Publication type:
    Article
    37
    38
    39

    Total serum N-glycans associate with response to immune checkpoint inhibition therapy and survival in patients with advanced melanoma.

    Published in:
    BMC Cancer, 2023, v. 23, n. 1, p. 1, doi. 10.1186/s12885-023-10511-3
    By:
    • Visconti, Alessia;
    • Rossi, Niccolò;
    • Deriš, Helena;
    • Lee, Karla A;
    • Hanić, Maja;
    • Trbojević-Akmačić, Irena;
    • Thomas, Andrew M.;
    • Bolte, Laura A.;
    • Björk, Johannes R.;
    • Hooiveld-Noeken, Jahlisa S.;
    • Board, Ruth;
    • Harland, Mark;
    • Newton-Bishop, Julia;
    • Harries, Mark;
    • Sacco, Joseph J.;
    • Lorigan, Paul;
    • Shaw, Heather M.;
    • de Vries, Elisabeth G.E.;
    • Fehrmann, Rudolf S.N.;
    • Weersma, Rinse K.
    Publication type:
    Article
    40
    41
    42
    43
    44

    Stroma remodeling and reduced cell division define durable response to PD-1 blockade in melanoma.

    Published in:
    Nature Communications, 2020, v. 11, n. 1, p. 1, doi. 10.1038/s41467-020-14632-2
    By:
    • Galvani, Elena;
    • Mundra, Piyushkumar A.;
    • Valpione, Sara;
    • Garcia-Martinez, Pablo;
    • Smith, Matthew;
    • Greenall, Jonathan;
    • Thakur, Rohit;
    • Helmink, Beth;
    • Andrews, Miles C.;
    • Boon, Louis;
    • Chester, Christopher;
    • Gremel, Gabriela;
    • Hogan, Kate;
    • Mandal, Amit;
    • Zeng, Kang;
    • Banyard, Antonia;
    • Ashton, Garry;
    • Cook, Martin;
    • Lorigan, Paul;
    • Wargo, Jennifer A.
    Publication type:
    Article
    45
    46
    47

    Circulating Tumour DNA in Melanoma—Clinic Ready?

    Published in:
    Current Oncology Reports, 2022, v. 24, n. 3, p. 363, doi. 10.1007/s11912-021-01151-6
    By:
    • Tivey, Ann;
    • Britton, Fiona;
    • Scott, Julie-Ann;
    • Rothwell, Dominic;
    • Lorigan, Paul;
    • Lee, Rebecca
    Publication type:
    Article
    48
    49
    50